Details of the Drug Combination

General Information of Drug Combination (ID: DCTG40W)

• Drug Combination Name: Difluprednate + Nepafenac
• Indication: Uveitis; Status: Phase 4 [1]
• Component Drugs:
  Difluprednate (DMMFVB3): Small molecular drug
  Nepafenac (DMYK490): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Difluprednate

Disease Entry	ICD 11	Status	REF
Ocular pain	MC18	Approved	[2]

Difluprednate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Phospholipase A2 inhibitory protein (PA2IP)	TTUCK4B	ANXA1_HUMAN	Agonist	[4]

Difluprednate Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]

Indication(s) of Nepafenac

Disease Entry	ICD 11	Status	REF
Osteoarthritis	FA00-FA05	Approved	[3]

Nepafenac Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN; PGH2_HUMAN	Inhibitor	[6]

References

• [1] ClinicalTrials.gov (NCT01939691) Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7474).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7564).
• [4] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [5] Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52.
• [6] Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.